Key facts
- This page summarizes Jason Drew Smith's Form 4 filing for UroGen Pharma Ltd. (URGN).
- 10 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 11 Feb 2026, 14:54.
Jason Drew Smith - 31 Jan 2026 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)
- Reporting relationship
- General Counsel
- Issuer ticker
- URGN
- Reported as of
- 31 Jan 2026
- Net transaction value
- -$147,262
- SEC form
- 4
- Accepted by SEC
- 11 Feb 2026, 14:54:58 UTC
- Prior SEC filing
- 09 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason D. Smith, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jason Drew Smith filed Form 4 for UroGen Pharma Ltd. (URGN) on 11 Feb 2026.
Change
- Previous filing in this sequence was filed on 09 Sep 2025.
- Current net transaction value: -$147,262.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001821479
Primary reporting owner
Smith Jason Drew
- Relationship
- General Counsel
- Address
- 400 ALEXANDER PARK DRIVE, PRINCETON
- Signature
- /s/ Jason D. Smith, Attorney-in-Fact
- Signature date
- 11 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
URGN
transaction
Ordinary Shares
Options Exercise
- Transaction value
- Shares
- +5,500
- Change %
- +11%
- Price
- Shares after
- 55,472
- Date
- 31 Jan 2026
- Ownership
- Direct
- Footnotes
- F1
URGN
transaction
Ordinary Shares
Sale
- Transaction value
- $52,257
- Shares
- -2,654
- Change %
- -4.8%
- Price
- $19.69
- Shares after
- 52,934
- Date
- 03 Feb 2026
- Ownership
- Direct
- Footnotes
- F2
URGN
transaction
Ordinary Shares
Options Exercise
- Transaction value
- Shares
- +3,333
- Change %
- +6%
- Price
- Shares after
- 58,805
- Date
- 31 Jan 2026
- Ownership
- Direct
- Footnotes
- F1
URGN
transaction
Ordinary Shares
Sale
- Transaction value
- $31,662
- Shares
- -1,608
- Change %
- -3%
- Price
- $19.69
- Shares after
- 51,326
- Date
- 03 Feb 2026
- Ownership
- Direct
- Footnotes
- F2
URGN
transaction
Ordinary Shares
Options Exercise
- Transaction value
- Shares
- +6,667
- Change %
- +15%
- Price
- Shares after
- 49,972
- Date
- 31 Jan 2026
- Ownership
- Direct
- Footnotes
- F1
URGN
transaction
Ordinary Shares
Sale
- Transaction value
- $63,343
- Shares
- -3,217
- Change %
- -5.5%
- Price
- $19.69
- Shares after
- 55,588
- Date
- 03 Feb 2026
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
URGN
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -5,500
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 5,500
- Date
- 31 Jan 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 5,500
- Exercise price
- Footnotes
- F1, F5
URGN
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -3,333
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 6,667
- Date
- 31 Jan 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 3,333
- Exercise price
- Footnotes
- F1, F3
URGN
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -6,667
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 31 Jan 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 6,667
- Exercise price
- Footnotes
- F1, F4
URGN
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +32,609
- Change %
- Price
- $0.000000
- Shares after
- 32,609
- Date
- 31 Jan 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 32,609
- Exercise price
- Footnotes
- F1, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
Footnote F2
Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
Footnote F3
The reporting person was granted RSUs on January 31, 2025 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2026.
Footnote F4
The reporting person was granted RSUs on January 31, 2023 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024.
Footnote F5
The reporting person was granted RSUs on January 31, 2024 representing 16,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025.
Footnote F6
1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029.